EZH2 is overexpressed in numerous tumor entities, including neuroblastoma, small cell carcinoma, and prostate cancer, and is frequently associated with aggressive disease, leading to its classification as an oncogene12,35. This evidence concerns the gene EZH2 and prostate carcinoma.